Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : SRNE save search
Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA™) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual Meeting
Published: 2022-05-06 (Crawled : 01:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -7.06%
H: 0.63%
C: -3.8%
sp-102 presentation phase 3
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA™) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management
Published: 2022-03-18 (Crawled : 14:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 0.0%
H: 5.41%
C: 1.16%
sp-102 program trial therapeutics phase 3
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial
Published: 2021-12-09 (Crawled : 22:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.03%
H: 2.75%
C: -2.6%
sp-102 trial therapeutics opioid positive results phase 3 topline
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class Therapy
Published: 2021-12-09 (Crawled : 17:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.03%
H: 2.75%
C: -2.6%
sp-102 trial therapeutics potential opioid positive therapy results phase 3 topline
Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management
Published: 2021-07-20 (Crawled : 17:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.58%
H: 1.39%
C: 0.25%
opioid phase 3 trial injection enroll
Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of Extensive-stage Small-Cell Lung Cancer
Published: 2021-03-08 (Crawled : 04:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 3.38%
H: 0.76%
C: -4.25%
treatment lung cancer cancer antibody license phase 3 trial clearance
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients
Published: 2021-03-02 (Crawled : 21:04) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.37%
H: 2.41%
C: -5.21%
covid fda clearance treatment fda phase 1 drop positive phase 3 phase 2 clearance
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in Healthy Volunteers and in Newly Diagnosed COVID-19 Patients
Published: 2020-12-09 (Crawled : 14:05) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 10.51%
H: 2.29%
C: -5.96%
covid fda clearance fda trial phase 3 phase 1 phase 2 clearance
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.